Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Conditions: Fallopian Tube Carcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Endometrioid Adenocarcinoma; Ovarian Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Cediranib Maleate; Procedure: Computed Tomography; Procedure: Echocardiography; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Drug: Olaparib; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI)
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 19, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments